← 治験一覧に戻る
持続性喘息患者におけるデュピルマブの評価（リバティ喘息クエスト）
基本情報
- NCT ID
- NCT02414854
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 1,902
- 治験依頼者名
- Sanofi
概要
Primary Objective: To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma. Secondary Objectives: * To evaluate the safety and tolerability of dupilumab. * To evaluate the effect of dupilumab on improving participant-reported outcomes including health-related quality of life. * To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.
対象疾患
Asthma
介入
Dupilumab(DRUG)
Placebo(DRUG)
Inhaled corticosteroid (ICS) therapy(DRUG)
Albuterol/Salbutamol(DRUG)
Levalbuterol/Levosalbutamol(DRUG)